S&P 500   4,269.65 (-0.09%)
DOW   33,520.77 (-0.29%)
QQQ   355.21 (+0.28%)
AAPL   171.35 (-0.35%)
MSFT   311.84 (-0.10%)
META   300.44 (+0.50%)
GOOGL   129.38 (+0.63%)
AMZN   125.31 (-0.53%)
TSLA   244.25 (+0.05%)
NVDA   423.54 (+1.06%)
NIO   8.41 (+0.00%)
BABA   86.06 (+0.17%)
AMD   98.68 (+2.83%)
T   14.96 (-0.40%)
F   12.43 (+0.00%)
MU   68.12 (+0.26%)
CGC   0.94 (+1.39%)
GE   111.17 (+1.13%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.19 (-0.65%)
PYPL   58.80 (-0.22%)
NFLX   382.50 (+0.86%)
S&P 500   4,269.65 (-0.09%)
DOW   33,520.77 (-0.29%)
QQQ   355.21 (+0.28%)
AAPL   171.35 (-0.35%)
MSFT   311.84 (-0.10%)
META   300.44 (+0.50%)
GOOGL   129.38 (+0.63%)
AMZN   125.31 (-0.53%)
TSLA   244.25 (+0.05%)
NVDA   423.54 (+1.06%)
NIO   8.41 (+0.00%)
BABA   86.06 (+0.17%)
AMD   98.68 (+2.83%)
T   14.96 (-0.40%)
F   12.43 (+0.00%)
MU   68.12 (+0.26%)
CGC   0.94 (+1.39%)
GE   111.17 (+1.13%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.19 (-0.65%)
PYPL   58.80 (-0.22%)
NFLX   382.50 (+0.86%)
S&P 500   4,269.65 (-0.09%)
DOW   33,520.77 (-0.29%)
QQQ   355.21 (+0.28%)
AAPL   171.35 (-0.35%)
MSFT   311.84 (-0.10%)
META   300.44 (+0.50%)
GOOGL   129.38 (+0.63%)
AMZN   125.31 (-0.53%)
TSLA   244.25 (+0.05%)
NVDA   423.54 (+1.06%)
NIO   8.41 (+0.00%)
BABA   86.06 (+0.17%)
AMD   98.68 (+2.83%)
T   14.96 (-0.40%)
F   12.43 (+0.00%)
MU   68.12 (+0.26%)
CGC   0.94 (+1.39%)
GE   111.17 (+1.13%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.19 (-0.65%)
PYPL   58.80 (-0.22%)
NFLX   382.50 (+0.86%)
S&P 500   4,269.65 (-0.09%)
DOW   33,520.77 (-0.29%)
QQQ   355.21 (+0.28%)
AAPL   171.35 (-0.35%)
MSFT   311.84 (-0.10%)
META   300.44 (+0.50%)
GOOGL   129.38 (+0.63%)
AMZN   125.31 (-0.53%)
TSLA   244.25 (+0.05%)
NVDA   423.54 (+1.06%)
NIO   8.41 (+0.00%)
BABA   86.06 (+0.17%)
AMD   98.68 (+2.83%)
T   14.96 (-0.40%)
F   12.43 (+0.00%)
MU   68.12 (+0.26%)
CGC   0.94 (+1.39%)
GE   111.17 (+1.13%)
DIS   80.37 (+0.40%)
AMC   7.90 (-0.13%)
PFE   32.19 (-0.65%)
PYPL   58.80 (-0.22%)
NFLX   382.50 (+0.86%)

LianBio (LIAN) Stock Forecast, Price & News

$1.50
0.00 (0.00%)
(As of 10:39 AM ET)
Compare
Today's Range
$1.46
$1.56
50-Day Range
$1.50
$2.23
52-Week Range
$1.07
$2.90
Volume
43,980 shs
Average Volume
221,621 shs
Market Capitalization
$160.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

LianBio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
900.0% Upside
$15.00 Price Target
Short Interest
Healthy
0.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.95) to ($1.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

685th out of 963 stocks

Pharmaceutical Preparations Industry

313th out of 452 stocks


LIAN stock logo

About LianBio (NASDAQ:LIAN) Stock

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LIAN Price History

LIAN Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Is This Just an Oversold Bounce? Let's Take What We Can Get
See More Headlines
Receive LIAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter.

LIAN Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIAN
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-110,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.71 per share

Miscellaneous

Free Float
99,034,000
Market Cap
$160.76 million
Optionable
Not Optionable
Beta
0.59
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Konstantin Poukalov (Age 39)
    Founder & Exec. Chairman
  • Dr. Yizhe Wang Ph.D. (Age 53)
    CEO & Director
    Comp: $1.34M
  • Ms. Yi Larson M.B.A. (Age 43)
    CFO & Treasurer
    Comp: $1.41M
  • Ms. Brianne Jahn (Age 37)
    Chief Bus. Officer
  • Mr. Jiang Qian (Age 54)
    Chief Commercial Officer & GM of China
  • Dr. Michael Humphries M.D.
    Chief Scientific Advisor













LIAN Stock - Frequently Asked Questions

Should I buy or sell LianBio stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIAN shares.
View LIAN analyst ratings
or view top-rated stocks.

What is LianBio's stock price forecast for 2023?

1 analysts have issued 1 year price objectives for LianBio's shares. Their LIAN share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price.
View analysts price targets for LIAN
or view top-rated stocks among Wall Street analysts.

How have LIAN shares performed in 2023?

LianBio's stock was trading at $1.64 at the beginning of 2023. Since then, LIAN stock has decreased by 8.5% and is now trading at $1.50.
View the best growth stocks for 2023 here
.

When is LianBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our LIAN earnings forecast
.

How were LianBio's earnings last quarter?

LianBio (NASDAQ:LIAN) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07.

What ETF holds LianBio's stock ?

Loncar China Biopharma ETF holds 27,778 shares of LIAN stock, representing 1.31% of its portfolio.

When did LianBio IPO?

(LIAN) raised $325 million in an initial public offering on the week of November 1st 2021. The company issued 20,300,000 shares at a price of $16.00 per share. Goldman Sachs, Jefferies and BofA Securities served as the underwriters for the IPO.

What is LianBio's stock symbol?

LianBio trades on the NASDAQ under the ticker symbol "LIAN."

Who are LianBio's major shareholders?

LianBio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.93%), Affinity Asset Advisors LLC (0.75%), Citigroup Inc. (0.66%), Renaissance Technologies LLC (0.29%), Acadian Asset Management LLC (0.13%) and MYDA Advisors LLC (0.13%).
View institutional ownership trends
.

How do I buy shares of LianBio?

Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LianBio's stock price today?

One share of LIAN stock can currently be purchased for approximately $1.50.

How much money does LianBio make?

LianBio (NASDAQ:LIAN) has a market capitalization of $160.76 million. The company earns $-110,290,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does LianBio have?

The company employs 163 workers across the globe.

How can I contact LianBio?

The official website for the company is www.lianbio.com. The company can be reached via phone at 609-486-2308 or via email at ir@lianbio.com.

This page (NASDAQ:LIAN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -